EU funds and incentives
Project: ‘Fundamental innovation of the production process of filling for products based on bulk powders. From manual to fully automatic.” co-financed by the European Union.
Name and registered office of the beneficiary:
BIOMIN, a.s.
Potočná 1/1, 919 43 Cífer
Project location:
Cífer
Non-returnable financial contribution:
64 450,00 EUR
Brief description of the project:
The project aims to achieve the following:
- Innovation of the production process of BIOMIN, a.s. in the production of products based on natural calcium as part of the complex of natural minerals contained in a unique source of natural calcium, in eggshells, as the only product of its kind on the market, which is a biopreparation without chemical additives, by introducing new dosage forms into the production. This objective will be achieved by procuring, installing and putting into production a new device: a pharmaceutical bulk dosing machine. This equipment will ensure the implementation of the defined innovations: automation of the production process from a manual working operation and an increase in the mass uniformity of the products, thus narrowing the tolerance band.
- Replacement of technological steps carried out manually by automated procedures associated with the elimination of the risk of product contamination, with a reduction in the error rate of dosing of bulk materials. The objective will be achieved by the acquisition, installation and introduction into production of the applicant’s automated bulk powder dosing machine, since the technological steps on this equipment will be carried out in a protected atmosphere after the introduction of the planned innovation, without the need for intervention in their course, which will also achieve the third objective.
- Improving occupational hygiene by reducing workers’ exposure to environments with increased dust.
“Information on the Operational Programme Integrated Infrastructure 2014-2020 can be found at www.opii.gov.sk”.
The project “Strategic industrial research and development of human drugs based on calcium bio-preparations for the prevention and treatment of osteological civilisation diseases” is co-financed by the European Union.
Name and registered office of the beneficiary:
BIOMIN, a.s.
Potočná 1/1, 919 43 Cífer
Project partner:
Comenius University in Bratislava
Project location:
Cífer
Non-returnable financial contribution:
EUR 1 236 625,05
Brief description of the project:
The main objective of the project is industrial research in conjunction with clinical research leading to a fundamental innovation of the dosage form of the active substance BIOMIN H with a simultaneous fundamental innovation of the technological process of production of the innovative drug. The outcome of the project will be a new more effective dosage form with a significantly more pleasant way of use than the original drug and a related fundamental innovation of the technological process of drug production
You need to put this text there:
“Information on the Operational Programme Integrated Infrastructure 2014-2020 can be found at www.opii.gov.sk”.
Project name:
Reconstruction of lighting and replacement of air conditioning
Brief description of the project:
The BIOMIN, a.s. energy savings project is aimed at reducing the company’s energy consumption in the production of medicines and supplements. The main parts of the project are heat recovery using an air handling unit, which will reduce the consumption of heat for heating, and the reconstruction of lighting in the production areas, which will reduce the consumption of electricity.
Project start date:
01/2018
Project end date:
10/2020
Grant:
121 852,44 EUR
Website
www.op-kzp.sk
www.siea.sk
Name and registered office of the beneficiary:
Biomedical Centre of the Slovak Academy of Sciences
Dúbravská cesta 9. 845 05 Bratislava
Name of the project:
Long-term strategic research on prevention, intervention and mechanisms of obesity and its comorbidities
Project partners:
Comenius University in Bratislava
Slovak University of Agriculture in Nitra
University of St. Cyril and Methodius in Trnava
BIOMIN, a..s
MABPRO. a. s.
AP2 s. r. o.
Project location:
Bratislava – Devínska Nova Ves,
Bratislava – Lamač district
Martin
Ruzomberok
Žilina, Košice – city part Juh
Nitra
Cífer
Špačince
Amount of NFA granted:
EUR 6 894 385,59
Brief description of the project:
The aim of the project is to contribute to the improvement of health and quality of life of the Slovak population suffering from obesity and its associated health complications and comorbidities by means of progressive research carried out by top scientific researchers from 4 academic and 3 industrial partners.
The main output of the project will be the creation of a functional model of the first Obesity Management Centre in the Slovak Republic, accredited by the European Association for the Study of Obesity (EASO), and its subsequent establishment and commissioning in a short timeframe after the end of the project. We expect that the CMO will enable improved supra-institutional management of obese patients through a comprehensive approach by experts based on current medical and scientific knowledge.
The project will also bring new scientific knowledge, practical applications, innovative products and contribute to raising public awareness (especially among young people) of the adverse effects of obesity on health and the progression of comorbidities, the benefits of obesity research, the opportunities for intervention and the importance of prevention and prophylaxis of obesity and its comorbidities.
The implementation of the project will stimulate public-private R&D and innovation cooperation between academic and business entities and improve their competitiveness.
“Information on the Operational Programme Integrated Infrastructure 2014-2020 can be found at www.opii.gov.sk”.
Recipient:
BIOMIN, a.s.
Name of the project:
Research on the extraction of active substances and their appropriate technological processing from egg membrane bio-waste
Project registration number:
2018/ 14569:10 – 26C0
Project implementation period:
12/2018 – 11/2021
Global Objective:
The aim of the project is to investigate the appropriate technological processing and subsequent use of the obtained raw material as a primary API (active product substance) in a new dosage form from the feedstock – biological waste generated in the food industry during the primary processing of eggs. In addition to obtaining and determination of the API itself, another output of the project will be the definition and testing in semi-operational conditions of a new production process and a complex of individual production operations in the processing and stabilization of the input target raw material. It is also necessary that the entire new process line meets the GMP (Good Manufacturing Practice) criteria in the pharmaceutical industry. The final output of the project will be a new API base substance for use in the pharmaceutical industry, which will have defined and known pharmacological properties. It will be further used as a basis for either a stand-alone – pure product or will serve as an active, enriching component in the production of multifactorial nutritional supplements. The API obtained will maintain the high natural bioavailability of the active components and thus provide the maximum possible benefits of a natural raw material. The final output of the project, namely the new natural API and its production process, will be an excellent, unique, Slovak, highly competitive advantage for further development of the industry segment.
Current status:
In 2020, the project met expectations and progressed according to planned milestones. We managed to build a complete pre-production line for processing primary API and to implement a number of test steps for each of its technological parts. The cumulative knowledge of the high-volume processing of primary API has shown critical points that will need to be fine-tuned before the production start-up date. Overall, however, it can be stated that the line concept in laboratory conditions has been built correctly, and the methods of processing primary API that will be used in the real production phase have been selected. The knowledge gained in this pre-production phase is a significant help in the conception of the final setup of the production line, and we evaluate all the steps of testing as very beneficial and helpful to optimize the planned result. We plan to subject the same critical points along with the need to further test the functionality of the crushing equipment in the next shell collection campaign, when sufficient API supply will be ensured.
We will use the summary of the tests to optimize the individual steps as well as to obtain enough raw material of the primary API to use for the bioassay. The planned goal of achieving an optimal ratio between the medical effect and the technological-energy intensity of the treatment based on the implementation of further pre-production tests seems to be achievable.
At the same time, after signing a contract with a new partner, we will conduct a scientific experiment to verify the effect of the final API already produced in our conditions. Experiment on a biological model – verification of bioavailability and effect on a living chondrocyte cell, and thus to trace the practical biological effect, the direct approximation of which can be expected anabasic effect in the human body when supplemented with a preparation based on the primary API developed by us.
Project name:
Reduction of energy consumption in the production hall of BIOMIN, a.s.
Brief description of the project:
The subject of the project is the implementation of the following energy measures:
- improving the thermal-technical parameters of the production hall by insulating the roof and replacing windows and doors;
- reconstruction of the gas boiler room as a heat source;
- installation of a PV plant on the roof of the production hall.
Thanks to the implementation of the project, BIOMIN, a.s. will achieve a reduction in the energy consumption of the production hall and will save the costs of electricity and gas consumption in the production of pharmaceutical products.
Project start date:
08/2021
Project completion date:
01/2023
Non-returnable financial contribution:
EUR 107 732,26
Website
www.op-kzp.sk
www.siea.sk
